

Last revision:	Document ID: 4005	Approved by: Rolf Røssland
Responsible: Fredrik Bærheim	Version: 1	Paper copies are not controlled. The controlled document is available on the NUI QA system.

## Summary Clinical Trial EduraCT 2019-000740-10

### Study information

- Study title: Hyperbaric oxygen therapy after cerebral infarction
- Test drug/investigational product: Medical oxygen MTnr: 11-8475
  - Product Code SUB14733MIG
  - Marketing Authorisation Holder: Air Liquide Norway (11-8626)
- Indication: Chronic physical and cognitive complications after cerebral infarction
- Sponsor: NUI As
- Protocol: 901809, date 2019-12-05
- US NCT: NCT04149379
- Study status: Prematurely ended December 11. 2019.
- Responsible medical officer: Svein Rune Solheimsnes
- Sponsor signatory: Fredrik Bærheim, [frb@nui.no](mailto:frb@nui.no), +4798090200

### Summary

This trial was planned as a pilot study where six patients with chronic physical and cognitive complications after cerebral infarction was planned to receive hyperbaric oxygen therapy at treatment table 14/90, 90 minutes, 5 days a week for 8 weeks. No placebo in control group.

Due to the corona pandemic 2019-2021 the clinical trial was prematurely ended December 11. 2019.

### Result

No patients (participants) was enrolled or treated.